West Pharmaceutical Services Free Cash Flow (FCF) History (WST)
West Pharmaceutical Services reported $468.9M in free cash flow for fiscal 2025, an increase of 69.65% from the previous fiscal year, with a free cash flow margin of 15.25%.
View full West Pharmaceutical Services company overviewWest Pharmaceutical Services free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $468.9M | $192.5M | +69.65% | +15.25% |
| 2024 | 2024-12-31 | $276.4M | −$138.1M | −33.32% | +9.55% |
| 2023 | 2023-12-31 | $414.5M | −$24.9M | −5.67% | +14.05% |
| 2022 | 2022-12-31 | $439.4M | $108.8M | +32.91% | +15.22% |
| 2021 | 2021-12-31 | $330.6M | $32.5M | +10.90% | +11.68% |
| 2020 | 2020-12-31 | $298.1M | $57.3M | +23.80% | +13.89% |
| 2019 | 2019-12-31 | $240.8M | $56.9M | +30.94% | +13.09% |
| 2018 | 2018-12-31 | $183.9M | $51.4M | +38.79% | +10.71% |
| 2017 | 2017-12-31 | $132.5M | $83.3M | +169.31% | +8.29% |
| 2016 | 2016-12-31 | $49.2M | −$31.6M | −39.11% | +3.26% |
| 2015 | 2015-12-31 | $80.8M | $9.8M | +13.80% | +5.77% |
| 2014 | 2014-12-31 | $71.0M | $2.4M | +3.50% | +5.00% |
| 2013 | 2013-12-31 | $68.6M | $12.5M | +22.28% | +5.01% |
| 2012 | 2012-12-31 | $56.1M | $20.8M | +58.92% | +4.43% |
| 2011 | 2011-12-31 | $35.3M | −$31.9M | −47.47% | +2.96% |
| 2010 | 2010-12-31 | $67.2M | $34.4M | +104.88% | +6.08% |
| 2009 | 2009-12-31 | $32.8M | $36.4M | — | +3.11% |
| 2008 | 2008-12-31 | −$3.6M | — | — | −0.34% |
West Pharmaceutical Services quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $80.8M | −$21.1M | −20.71% | +9.26% |
| Q1 2026 | 2026-03-31 | $47.2M | −$10.9M | −18.76% | +5.59% |
| Q4 2025 | 2025-12-31 | $175.0M | $89.8M | +105.40% | +21.74% |
| Q3 2025 | 2025-09-30 | $133.9M | $35.1M | +35.53% | +16.64% |
| Q2 2025 | 2025-06-30 | $101.9M | $37.1M | +57.25% | +13.29% |
| Q1 2025 | 2025-03-31 | $58.1M | $30.5M | +110.51% | +8.32% |
| Q4 2024 | 2024-12-31 | $85.2M | −$45.2M | −34.66% | +11.38% |
| Q3 2024 | 2024-09-30 | $98.8M | −$35.5M | −26.43% | +13.23% |
| Q2 2024 | 2024-06-30 | $64.8M | −$29.0M | −30.92% | +9.23% |
| Q1 2024 | 2024-03-31 | $27.6M | −$28.4M | −50.71% | +3.97% |
| Q4 2023 | 2023-12-31 | $130.4M | −$5.5M | −4.05% | +17.81% |
| Q3 2023 | 2023-09-30 | $134.3M | $23.2M | +20.88% | +17.97% |
| Q2 2023 | 2023-06-30 | $93.8M | −$13.2M | −12.34% | +12.44% |
| Q1 2023 | 2023-03-31 | $56.0M | −$29.4M | −34.43% | +7.81% |
| Q4 2022 | 2022-12-31 | $135.9M | $51.6M | +61.21% | +19.18% |
| Q3 2022 | 2022-09-30 | $111.1M | −$13.7M | −10.98% | +16.17% |
| Q2 2022 | 2022-06-30 | $107.0M | $19.5M | +22.29% | +13.87% |
| Q1 2022 | 2022-03-31 | $85.4M | $51.4M | +151.18% | +11.86% |
| Q4 2021 | 2021-12-31 | $84.3M | −$6.7M | −7.36% | +11.54% |
| Q3 2021 | 2021-09-30 | $124.8M | $53.7M | +75.53% | +17.66% |
| Q2 2021 | 2021-06-30 | $87.5M | −$23.5M | −21.17% | +12.09% |
| Q1 2021 | 2021-03-31 | $34.0M | $9.0M | +36.00% | +5.07% |
| Q4 2020 | 2020-12-31 | $91.0M | $22.2M | +32.27% | +15.68% |
| Q3 2020 | 2020-09-30 | $71.1M | −$5.3M | −6.94% | +12.97% |
| Q2 2020 | 2020-06-30 | $111.0M | $34.2M | +44.53% | +21.05% |
| Q1 2020 | 2020-03-31 | $25.0M | $6.2M | +32.98% | +5.09% |
| Q4 2019 | 2019-12-31 | $68.8M | $25.6M | +59.26% | +14.62% |
| Q3 2019 | 2019-09-30 | $76.4M | $14.5M | +23.42% | +16.75% |
| Q2 2019 | 2019-06-30 | $76.8M | $15.0M | +24.27% | +16.35% |
| Q1 2019 | 2019-03-31 | $18.8M | $1.8M | +10.59% | +4.24% |
| Q4 2018 | 2018-12-31 | $43.2M | −$8.8M | −16.92% | +10.22% |
| Q3 2018 | 2018-09-30 | $61.9M | $20.4M | +49.16% | +14.34% |
| Q2 2018 | 2018-06-30 | $61.8M | $6.0M | +10.75% | +13.81% |
| Q1 2018 | 2018-03-31 | $17.0M | $33.8M | — | +4.09% |
| Q4 2017 | 2017-12-31 | $52.0M | $27.7M | +113.99% | +12.51% |
| Q3 2017 | 2017-09-30 | $41.5M | $21.8M | +110.66% | +10.42% |
| Q2 2017 | 2017-06-30 | $55.8M | $14.6M | +35.44% | +14.03% |
| Q1 2017 | 2017-03-31 | −$16.8M | $19.2M | — | −4.33% |
| Q4 2016 | 2016-12-31 | $24.3M | $1.1M | +4.74% | +6.36% |
| Q3 2016 | 2016-09-30 | $19.7M | −$19.4M | −49.62% | +5.23% |
| Q2 2016 | 2016-06-30 | $41.2M | −$9.6M | −18.90% | +10.62% |
| Q1 2016 | 2016-03-31 | −$36.0M | −$3.7M | — | −9.94% |
| Q4 2015 | 2015-12-31 | $23.2M | $4.3M | +22.75% | +6.45% |
| Q3 2015 | 2015-09-30 | $39.1M | $3.8M | +10.76% | +11.35% |
| Q2 2015 | 2015-06-30 | $50.8M | $11.1M | +27.96% | +14.12% |
| Q1 2015 | 2015-03-31 | −$32.3M | −$9.4M | — | −9.62% |
| Q4 2014 | 2014-12-31 | $18.9M | −$11.1M | −37.00% | +5.40% |
| Q3 2014 | 2014-09-30 | $35.3M | $11.3M | +47.08% | +9.92% |
| Q2 2014 | 2014-06-30 | $39.7M | −$17.7M | −30.84% | +10.76% |
| Q1 2014 | 2014-03-31 | −$22.9M | $19.9M | — | −6.60% |
| Q4 2013 | 2013-12-31 | $30.0M | −$6.9M | −18.70% | +8.75% |
| Q3 2013 | 2013-09-30 | $24.0M | $1.4M | +6.19% | +7.02% |
| Q2 2013 | 2013-06-30 | $57.4M | $42.2M | +277.63% | +16.66% |
| Q1 2013 | 2013-03-31 | −$42.8M | −$24.2M | — | −12.61% |
| Q4 2012 | 2012-12-31 | $36.9M | $28.5M | +339.29% | +11.48% |
| Q3 2012 | 2012-09-30 | $22.6M | $7.1M | +45.81% | +7.44% |
| Q2 2012 | 2012-06-30 | $15.2M | −$6.1M | −28.64% | +4.68% |
| Q1 2012 | 2012-03-31 | −$18.6M | −$8.7M | — | −5.88% |
| Q4 2011 | 2011-12-31 | $8.4M | −$17.5M | −67.57% | +2.84% |
| Q3 2011 | 2011-09-30 | $15.5M | −$15.3M | −49.68% | +5.28% |
| Q2 2011 | 2011-06-30 | $21.3M | $4.6M | +27.54% | +6.92% |
| Q1 2011 | 2011-03-31 | −$9.9M | −$3.7M | — | −3.35% |
| Q4 2010 | 2010-12-31 | $25.9M | $14.5M | +127.19% | +9.36% |
| Q3 2010 | 2010-09-30 | $30.8M | — | — | +11.35% |
| Q2 2010 | 2010-06-30 | $16.7M | — | — | +5.93% |
| Q1 2010 | 2010-03-31 | −$6.2M | — | — | −2.26% |
| Q3 2009 | 2009-09-30 | $11.4M | — | — | +4.40% |
West Pharmaceutical Services free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $298.1M to $468.9M, a compound annual growth rate of 9.48%. West Pharmaceutical Services's latest reported quarter, Q2 2026, generated $80.8M in free cash flow, a decrease of 20.71% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review West Pharmaceutical Services filings at SEC.gov ↗